首页 > 最新文献

Journal of Drugs in Dermatology最新文献

英文 中文
Opt for Methotrexate Before Biologics in the Treatment of Recalcitrant Delayed-Onset Reactions to Dermal Fillers. 在使用生物制剂治疗皮肤填充剂引起的顽固性迟发性反应之前,选择甲氨蝶呤。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
George Kroumpouzos, Marina Landau
{"title":"Opt for Methotrexate Before Biologics in the Treatment of Recalcitrant Delayed-Onset Reactions to Dermal Fillers.","authors":"George Kroumpouzos, Marina Landau","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Brief Report of 13 Cases of Poppers Dermatitis. 13 例流行性皮炎的简要报告
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
Vincent A Pecora, Sara Abdel Azim, Erika McCormick, Adam Friedman
{"title":"A Brief Report of 13 Cases of Poppers Dermatitis.","authors":"Vincent A Pecora, Sara Abdel Azim, Erika McCormick, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FULL SUPPLEMENT: Targeting Acne Pathogenesis with Topical Therapies. 完全补充:针对痤疮发病机制的局部疗法。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
Emmy M Graber

We, as dermatologists, are exceedingly lucky.  We can watch our patients improve before our eyes. In clinical practice, we don't often track a quantitative metric to gauge success but rather measure the success of our treatment by the appearance of our patients' skin.

作为皮肤科医生,我们非常幸运。我们可以亲眼看到患者的病情得到改善。在临床实践中,我们通常不会采用量化指标来衡量成功与否,而是通过患者的皮肤外观来衡量治疗的成功与否。
{"title":"FULL SUPPLEMENT: Targeting Acne Pathogenesis with Topical Therapies.","authors":"Emmy M Graber","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We, as dermatologists, are exceedingly lucky.&nbsp; We can watch our patients improve before our eyes. In clinical practice, we don't often track a quantitative metric to gauge success but rather measure the success of our treatment by the appearance of our patients' skin.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypochlorous Acid: A Blast from the Past. 次氯酸:过去的爆炸
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
Nikita Menta, Savanna I Vidal, Adam Friedman
{"title":"Hypochlorous Acid: A Blast from the Past.","authors":"Nikita Menta, Savanna I Vidal, Adam Friedman","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
INDIVIDUAL ARTCLE: Pathophysiologic Targets of Acne Treatment. 个人文章:痤疮治疗的病理生理学目标。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
Emmy M Graber, Natalie Vincent

Acne vulgaris is an extremely common dermatologic condition. Individuals with acne present not only to dermatologists, but also to internists, family medicine physicians, pediatricians, estheticians, and beauty counters alike in search of a treatment. The diagnosis of acne is relatively straightforward, leading many to believe that acne is a simple condition. However, the pathophysiology of acne is anything but simple. Decades of research has ultimately revealed a complex interaction of pathogenic factors that lead to acne. This includes sebum production, C. acnes colonization, inflammation, and follicular hyperkeratinization. Understanding each of these features has been fundamental to the development of anti-acne medications. Topical agents are often used as an initial therapy given their safety and efficacy. While some topical therapies have been used for decades, new creams, gels, and lotions continue to be added to the list of approved acne treatments. Given the number of topical acne products on the market, we present an updated review of the current landscape of topical acne treatments and how each choice functions mechanistically to fight against acne. J Drugs Dermatol. 2024;23:10(Suppl 1):s4-11.

寻常痤疮是一种极为常见的皮肤病。痤疮患者不仅向皮肤科医生求诊,还向内科医生、家庭医生、儿科医生、美容师和美容专柜寻求治疗。痤疮的诊断相对简单,因此很多人认为痤疮是一种简单的疾病。然而,痤疮的病理生理学却并不简单。数十年的研究最终揭示了导致痤疮的各种致病因素之间复杂的相互作用。这包括皮脂分泌、痤疮丙酸杆菌定植、炎症和毛囊角化过度。对这些特征的了解是开发抗痤疮药物的基础。鉴于其安全性和有效性,外用药物通常被用作初始疗法。虽然有些外用疗法已经使用了几十年,但不断有新的药膏、凝胶和乳液加入到批准的痤疮治疗清单中。鉴于市场上的痤疮外用产品数量众多,我们将对目前的痤疮外用治疗方法以及每种选择如何从机理上对抗痤疮进行最新评述。J Drugs Dermatol.2024;23:10(Suppl 1):s4-11.
{"title":"INDIVIDUAL ARTCLE: Pathophysiologic Targets of Acne Treatment.","authors":"Emmy M Graber, Natalie Vincent","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Acne vulgaris is an extremely common dermatologic condition. Individuals with acne present not only to dermatologists, but also to internists, family medicine physicians, pediatricians, estheticians, and beauty counters alike in search of a treatment. The diagnosis of acne is relatively straightforward, leading many to believe that acne is a simple condition. However, the pathophysiology of acne is anything but simple. Decades of research has ultimately revealed a complex interaction of pathogenic factors that lead to acne. This includes sebum production, C. acnes colonization, inflammation, and follicular hyperkeratinization. Understanding each of these features has been fundamental to the development of anti-acne medications. Topical agents are often used as an initial therapy given their safety and efficacy. While some topical therapies have been used for decades, new creams, gels, and lotions continue to be added to the list of approved acne treatments. Given the number of topical acne products on the market, we present an updated review of the current landscape of topical acne treatments and how each choice functions mechanistically to fight against acne. J Drugs Dermatol. 2024;23:10(Suppl 1):s4-11.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment. 关于金黄色葡萄球菌加重特应性皮炎和需要新型治疗方法的共识。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01 DOI: 10.36849/JDD.2024.8240
Lawrence A Schachner, Anneke Andriessen, Mercedes E Gonzalez, Karan Lal, Adelaide A Hebert, Lawrence F Eichenfield, Peter Lio

The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus) burden and atopic dermatitis (AD) severity. Managing S. aureuss-driven AD in clinical practice remains problematic due to complications such as AD exacerbation, impetigo, abscesses, and invasive infections. This project used a modified Delphi process comprising face-to-face discussions followed by a blinded vote to define 5 final consensus statements. A panel of 6 pediatric dermatologists developed a consensus on S. aureus-driven AD exacerbation, challenges in current treatments for AD with secondary bacterial infections, and new developments to improve patient care and outcomes. The panel's 5 consensus statements provide recommendations for dermatologists, pediatricians, and healthcare providers treating patients with secondary infected AD. These recommendations underscore the importance of recognizing and managing S. aureus skin infection in AD clinical practice and promoting antibiotic stewardship to mitigate resistance. The panel defined a significant unmet need for a single topical AD therapy effective against all symptoms, including pruritus, S. aureus-driven AD exacerbation, infection, and inflammation, across AD severity levels. J Drugs Dermatol. 2024;23(10):825-832. doi:10.36849/JDD.8240.

皮肤微生物群对皮肤屏障功能至关重要,因为它能抑制病原体的定植,而微生物群多样性的减少与金黄色葡萄球菌(S. aureus)负担的增加和特应性皮炎(AD)的严重程度相关。由于特应性皮炎加重、脓疱疮、脓肿和侵袭性感染等并发症,在临床实践中处理金黄色葡萄球菌引起的特应性皮炎仍然是个问题。该项目采用了改良的德尔菲流程,包括面对面讨论和盲法投票,最终确定了 5 项共识声明。由 6 位儿科皮肤科医生组成的专家小组就金黄色葡萄球菌引起的 AD 加剧、目前治疗 AD 继发细菌感染所面临的挑战以及改善患者护理和治疗效果的新进展达成了共识。专家组的 5 项共识声明为皮肤科医生、儿科医生和医护人员治疗继发感染 AD 患者提供了建议。这些建议强调了在 AD 临床实践中识别和管理金黄色葡萄球菌皮肤感染以及促进抗生素管理以减少耐药性的重要性。专家小组确定了一个重要的未满足需求,即需要一种单一的AD局部疗法,这种疗法能有效治疗AD严重程度不同的所有症状,包括瘙痒、金黄色葡萄球菌引起的AD恶化、感染和炎症。J Drugs Dermatol.2024;23(10):825-832. doi:10.36849/JDD.8240.
{"title":"A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment.","authors":"Lawrence A Schachner, Anneke Andriessen, Mercedes E Gonzalez, Karan Lal, Adelaide A Hebert, Lawrence F Eichenfield, Peter Lio","doi":"10.36849/JDD.2024.8240","DOIUrl":"10.36849/JDD.2024.8240","url":null,"abstract":"<p><p>The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus) burden and atopic dermatitis (AD) severity. Managing S. aureuss-driven AD in clinical practice remains problematic due to complications such as AD exacerbation, impetigo, abscesses, and invasive infections. This project used a modified Delphi process comprising face-to-face discussions followed by a blinded vote to define 5 final consensus statements. A panel of 6 pediatric dermatologists developed a consensus on S. aureus-driven AD exacerbation, challenges in current treatments for AD with secondary bacterial infections, and new developments to improve patient care and outcomes. The panel's 5 consensus statements provide recommendations for dermatologists, pediatricians, and healthcare providers treating patients with secondary infected AD. These recommendations underscore the importance of recognizing and managing S. aureus skin infection in AD clinical practice and promoting antibiotic stewardship to mitigate resistance. The panel defined a significant unmet need for a single topical AD therapy effective against all symptoms, including pruritus, S. aureus-driven AD exacerbation, infection, and inflammation, across AD severity levels. J Drugs Dermatol. 2024;23(10):825-832. doi:10.36849/JDD.8240.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors. JAKis 的 ABC:系统性 JAK 抑制剂的安全性和监测临床医师指南》(The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors)。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01 DOI: 10.36849/JDD.2024.8073
Dharm Sodha, Peter Lio, Linda Stein Gold

Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed warning. Here we discuss the safe and effective use of JAKs for the treatment of a wide variety of dermatologic conditions. We will also discuss monitoring guidelines. J Drugs Dermatol. 2024;23(10):852-856. doi:10.36849/JDD.8073.

Janus 激酶抑制剂(JAKis)是最近出现的治疗皮肤病的工具。然而,由于这些药物的盒装警告,人们对这些治疗方法存在一些担忧。在此,我们将讨论如何安全有效地使用 JAKs 治疗各种皮肤病。我们还将讨论监测指南。J Drugs Dermatol.2024;23(10):852-856. doi:10.36849/JDD.8073.
{"title":"The ABCs of JAKis: A Clinician's Guide to Safety and Monitoring of the Systemic JAK Inhibitors.","authors":"Dharm Sodha, Peter Lio, Linda Stein Gold","doi":"10.36849/JDD.2024.8073","DOIUrl":"10.36849/JDD.2024.8073","url":null,"abstract":"<p><p>Janus kinase inhibitors (JAKis) have recently emerged in the arsenal of tools to treat dermatological conditions. However, there are some concerns regarding these treatments due to their boxed warning. Here we discuss the safe and effective use of JAKs for the treatment of a wide variety of dermatologic conditions. We will also discuss monitoring guidelines. J Drugs Dermatol. 2024;23(10):852-856. doi:10.36849/JDD.8073.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema. 评估轻度湿疹患者使用的罗氟司特乳膏载体与含神经酰胺的保湿乳膏的效果。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01 DOI: 10.36849/JDD.2024.7958
Zoe Diana Draelos, Robert C Higham, David W Osborne, Melissa S Seal, Patrick Burnett, David R Berk

Background: Inflammatory dermatologic conditions suitable for topical treatments benefit from a hydrating vehicle that improves the skin barrier without irritation.

Objective: This research was designed to assess skin barrier effects and aesthetic attributes of the vehicle for topical roflumilast cream (vehicle) vs a currently marketed ceramide-containing moisturizing cream (moisturizer).

Methods: This was a single-site, randomized, intraindividual, double-blind, controlled study conducted over 17 days. Patients (aged 18 years or older) with mild, symmetric asteatotic eczema of the lower extremities were enrolled to receive lower leg applications of the vehicle on one leg and moisturizer on the other. The primary efficacy endpoint was a change in transepidermal water loss (TEWL) from baseline to day 15. Secondary efficacy endpoints included change from baseline in TEWL at other study visits, change from baseline in hydration as assessed via corneometry, and patient- and investigator-rated assessments of the products. Safety and tolerability were also assessed.

Results: A total of 40 patients enrolled in the study. The primary efficacy endpoint was met for both treatments. A statistically significant difference in TEWL on day 1 favored the moisturizer, but no difference was seen between vehicle and moisturizer at any other timepoint. Both vehicle and moisturizer also met the secondary efficacy endpoint of change from baseline in hydration.

Limitations: The sample size was small.

Conclusions: The vehicle for roflumilast cream performed similarly to a leading, currently marketed, dermatologist-recommended, ceramide-containing moisturizer across all patient- and investigator-rated assessments of efficacy, tolerability, and aesthetic properties in patients with mild asteatotic eczema. J Drugs Dermatol. 2024;23(10):834-840. doi:10.36849/JDD.7958  .

背景:适合局部治疗的炎症性皮肤病可从保湿载体中获益,这种载体可在不产生刺激的情况下改善皮肤屏障:本研究旨在评估外用罗氟司特乳膏载体(载体)与目前市场上销售的含神经酰胺保湿乳膏(保湿霜)的皮肤屏障效应和美学属性:这是一项为期 17 天的单点、随机、个体内、双盲对照研究。入组患者(18 岁或以上)患有轻度、对称性下肢湿疹,一条腿使用载体,另一条腿使用保湿霜。主要疗效终点是经表皮失水(TEWL)从基线到第 15 天的变化。次要疗效终点包括其他研究访问时经表皮失水率(TEWL)与基线相比的变化、通过角膜测量法评估的水合度与基线相比的变化以及患者和研究人员对产品的评价。此外,还对安全性和耐受性进行了评估:共有 40 名患者参加了研究。两种疗法均达到了主要疗效终点。第 1 天的 TEWL 差异具有统计学意义,保湿剂更胜一筹,但在任何其他时间点,载体和保湿剂之间均无差异。载体和保湿剂也都达到了次要疗效终点,即水合作用从基线开始的变化:局限性:样本量较小:结论:罗氟米司特乳膏的载体在轻度骨化性湿疹患者的疗效、耐受性和美学特性的所有患者和研究者评分评估中,表现与目前市场上领先的、皮肤科医生推荐的含神经酰胺的保湿霜相似。J Drugs Dermatol.DOI:10.36849/JDD.7958  .
{"title":"Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema.","authors":"Zoe Diana Draelos, Robert C Higham, David W Osborne, Melissa S Seal, Patrick Burnett, David R Berk","doi":"10.36849/JDD.2024.7958","DOIUrl":"10.36849/JDD.2024.7958","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory dermatologic conditions suitable for topical treatments benefit from a hydrating vehicle that improves the skin barrier without irritation.</p><p><strong>Objective: </strong>This research was designed to assess skin barrier effects and aesthetic attributes of the vehicle for topical roflumilast cream (vehicle) vs a currently marketed ceramide-containing moisturizing cream (moisturizer).</p><p><strong>Methods: </strong>This was a single-site, randomized, intraindividual, double-blind, controlled study conducted over 17 days. Patients (aged 18 years or older) with mild, symmetric asteatotic eczema of the lower extremities were enrolled to receive lower leg applications of the vehicle on one leg and moisturizer on the other. The primary efficacy endpoint was a change in transepidermal water loss (TEWL) from baseline to day 15. Secondary efficacy endpoints included change from baseline in TEWL at other study visits, change from baseline in hydration as assessed via corneometry, and patient- and investigator-rated assessments of the products. Safety and tolerability were also assessed.</p><p><strong>Results: </strong>A total of 40 patients enrolled in the study. The primary efficacy endpoint was met for both treatments. A statistically significant difference in TEWL on day 1 favored the moisturizer, but no difference was seen between vehicle and moisturizer at any other timepoint. Both vehicle and moisturizer also met the secondary efficacy endpoint of change from baseline in hydration.</p><p><strong>Limitations: </strong>The sample size was small.</p><p><strong>Conclusions: </strong>The vehicle for roflumilast cream performed similarly to a leading, currently marketed, dermatologist-recommended, ceramide-containing moisturizer across all patient- and investigator-rated assessments of efficacy, tolerability, and aesthetic properties in patients with mild asteatotic eczema. J Drugs Dermatol. 2024;23(10):834-840. doi:10.36849/JDD.7958 &nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Hyperhidrosis and Sensitive Skin: Exploring the Link with Predictive Machine Learning-Based Classification Models. 原发性多汗症与敏感性皮肤:探索基于预测性机器学习分类模型的联系。
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01 DOI: 10.36849/JDD.2024.8461
Erika T McCormick, Joung Min Choi, Sara Abdel Azim, Cleo Whiting, Lisa Pieretti, Liqing Zhang, Adam Friedman

Background: Primary hyperhidrosis (PHH) is a disorder of excessive sweating caused by aberrant cholinergic signaling. Sensitive skin (SS) is a condition of subjective cutaneous hyperreactivity to innocuous stimuli, impacting 40% to 70% of the population. SS is exacerbated by sweat, stress, and heat, suggesting that cholinergic stimulation may contribute to SS flares.

Objective: To survey PHH sufferers to assess hyperhidrosis (HH) and SS symptom burden.

Methods: An International Review Board (IRB)-exempt survey was disseminated by the International Hyperhidrosis Society. A predictive classification model for SS was built using random forest machine learning algorithms.

Results: Of the 637 respondents with PHH, 89% reported SS; and there was a significant association between HH and SS severity scores. Importantly, SS occurred on body sites affected and unaffected by HH. Predictive modeling designated Sensitive Scale-10 (SS-10), a validated questionnaire to gauge SS severity, to be the most helpful in predicting SS in this cohort.

Limitations: Self-reported data.

Conclusion: These data are the first to propose and support a relationship between SS and HH. SS occurred with greatest frequency at HH-afflicted body sites, but also occurred on unaffected sites, suggesting that sweat is not the sole causative link. Future work can explore cholinergic signaling as a potential link between these conditions. Screening HH patients for SS may be warranted. J Drugs Dermatol. 2024;23(10):882-888. doi:10.36849/JDD.8461.

背景:原发性多汗症(PHH)是一种由胆碱能信号传导异常引起的多汗症。敏感性皮肤(SS)是一种对无害刺激的主观皮肤高反应性疾病,影响着 40% 至 70% 的人群。出汗、压力和高温都会加剧皮肤敏感,这表明胆碱能刺激可能是导致皮肤敏感发作的原因之一:调查 PHH 患者,评估多汗症(HH)和 SS 症状负担:方法:国际多汗症协会发布了一项获得国际审查委员会(IRB)豁免的调查。采用随机森林机器学习算法建立了 SS 预测分类模型:结果:在 637 名 PHH 受访者中,89% 报告了 SS;HH 和 SS 严重程度评分之间存在显著关联。重要的是,SS 发生在受 HH 影响和未受 HH 影响的身体部位。预测模型显示,衡量SS严重程度的有效问卷Sensitive Scale-10(SS-10)最有助于预测该人群中的SS:局限性:自我报告数据:这些数据首次提出并支持 SS 与 HH 之间的关系。受 HH 影响的身体部位出现 SS 的频率最高,但未受影响的部位也会出现 SS,这表明汗液并不是唯一的致病因素。未来的工作可以探索胆碱能信号转导与这些疾病之间的潜在联系。可能需要对 HH 患者进行 SS 筛查。J Drugs Dermatol.2024;23(10):882-888. doi:10.36849/JDD.8461.
{"title":"Primary Hyperhidrosis and Sensitive Skin: Exploring the Link with Predictive Machine Learning-Based Classification Models.","authors":"Erika T McCormick, Joung Min Choi, Sara Abdel Azim, Cleo Whiting, Lisa Pieretti, Liqing Zhang, Adam Friedman","doi":"10.36849/JDD.2024.8461","DOIUrl":"https://doi.org/10.36849/JDD.2024.8461","url":null,"abstract":"<p><strong>Background: </strong>Primary hyperhidrosis (PHH) is a disorder of excessive sweating caused by aberrant cholinergic signaling. Sensitive skin (SS) is a condition of subjective cutaneous hyperreactivity to innocuous stimuli, impacting 40% to 70% of the population. SS is exacerbated by sweat, stress, and heat, suggesting that cholinergic stimulation may contribute to SS flares.</p><p><strong>Objective: </strong>To survey PHH sufferers to assess hyperhidrosis (HH) and SS symptom burden.</p><p><strong>Methods: </strong>An International Review Board (IRB)-exempt survey was disseminated by the International Hyperhidrosis Society. A predictive classification model for SS was built using random forest machine learning algorithms.</p><p><strong>Results: </strong>Of the 637 respondents with PHH, 89% reported SS; and there was a significant association between HH and SS severity scores. Importantly, SS occurred on body sites affected and unaffected by HH. Predictive modeling designated Sensitive Scale-10&nbsp;(SS-10), a validated questionnaire to gauge SS severity, to be the most helpful in predicting SS in this cohort.</p><p><strong>Limitations: </strong>Self-reported data.</p><p><strong>Conclusion: </strong>These data are the first to propose and support a relationship between SS and HH. SS occurred with greatest frequency at HH-afflicted body sites, but also occurred on unaffected sites, suggesting that sweat is not the sole causative link. Future work can explore cholinergic signaling as a potential link between these conditions. Screening HH patients for SS may be warranted. J Drugs Dermatol. 2024;23(10):882-888. doi:10.36849/JDD.8461.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis. 结构洞察:是什么让某些 IL-23 生物制剂对银屑病更有效?
IF 1.5 4区 医学 Q3 DERMATOLOGY Pub Date : 2024-10-01
Stefano G Daniele, Fabrizio Galimberti, Christopher G Bunick
{"title":"Structural Insights: What Makes Some IL-23 Biologics More Effective in Psoriasis.","authors":"Stefano G Daniele, Fabrizio Galimberti, Christopher G Bunick","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Drugs in Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1